Clinical trials: Long Term Follow-up
Overweight, Obesity
Long-term Health and Economic Effects of an Individualized Lifestyle Intervention (LI-PAD-Extended)
The goal of this clinical trial is to learn if an individualized lifestyle intervention works to improve weight, diet, physical activity, cardiovascular health, health-related quality of life, and cost-effectiveness in overweight…
- Conditions
- Overweight, Obesity, Prediabetic State
- Trial name
- LI-PAD-EXTENDE (NCT07605169)
- Testing
- Individualized physical activity and diet
- Where
- Sweden
- Volunteers
- 103 people
- Sponsor
- Vastra Gotaland Region
Anemia, Kidney Diseases
DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)
This is a post-authorisation safety study to assess the incidence and severity of all pre-defined cardiovascular events in patients treated with DYNEPO, as well as to detect \& describe less common adverse drug reactions, and to…
- Conditions
- Anemia, Kidney Diseases, Renal Failure, Chronic, Kidney Failure, Chronic
- Trial name
- DELFT (NCT00664066)
- Testing
- DYNEPO (epoetin delta)
- Where
- 2 sites in Germany
- Volunteers
- 3 people
- Sponsor
- Shire
Crohn's Disease
Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease
The study will continue to assess the safety of certolizumab pegol (CDP870) as well as examine the evolution of long term efficacy in Crohn's disease patients who completed study C87042 [NCT00308581].
- Trial name
- Welcome2 (NCT00333788)
- Testing
- Certolizumab pegol (CDP870)
- Where
- 65 sites in United States, Austria and 10 more
- Volunteers
- 233 people
- Sponsor
- UCB Pharma
Native Right Ventricle Outflow Tract(RVOT) Dysfunction
VenusP-Valve™ System Long-term Follow-up 6-10 Years
The goal of this study is to assess the long-term safety, efficacy and performance of VenusP-Valve™ implantation. in all subjects who provided informed consent and received VenusP-Valve™ implantation in the VenusP-Valve™ system…
- Trial name
- NCT07531303
- Volunteers
- 55 people
- Sponsor
- Venus MedTech (HangZhou) Inc.
Chronic Hepatitis b
Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
This trial is a multi-center, open, single-dose, dose-increasing trial，to evaluate the safety and efficacy of STSG-0002 injection in patients with chronic hepatitis B treated with oral antiviral therapy(Long-term follow-up).
- Trial name
- NCT05760703
- Testing
- STSG-0002 Injection
- Where
- 4 sites in China
- Volunteers
- 9 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Nasopharyngeal Carcinoma (NPC)
Validation of the 9th AJCC Staging System for NPC in Non-High-Incidence Areas in China
Background: Nasopharyngeal carcinoma (NPC) is a malignancy with marked geographic variation, with over 80% of global cases found in Southeast and East Asia.
- Trial name
- NCT07088861
- Volunteers
- 1,401 people
- Sponsor
- Lirong Wu
Degenerative Sacroilitis, Sacroiliac Joint Disruption
LOIS: Long-Term Follow-Up in INSITE/SIFI
The purpose of this study is to evaluate the long term safety and effectiveness of SI joint fusion using the iFuse Implant System in patients with degenerative sacroiliitis (DS) and/or sacroiliac joint disruptions (SD).
- Trial name
- LOIS (NCT02270203)
- Testing
- Pelvic CT at 5 years post-op
- Where
- 12 sites in United States
- Volunteers
- 103 people
- Sponsor
- SI-BONE, Inc.
Stress Urinary Incontinence
Long-term Effectiveness of Non-ablative Er: YAG Laser for Treatment of Stress Urinary Incontinence (SUI)
Study is designed to assess the long-term clinical effects and safety profile of non-ablative Er:YAG (IncontiLase®) laser treatment, the durability of the results and the optimal treatment regimen for mild-to-severe stages of…
- Trial name
- NCT04348994
- Testing
- Non-ablative thermal-only Er:YAG laser therapy
- Volunteers
- 43 people
- Sponsor
- Adrian Gaspar
Rheumatoid Arthritis (RA)
Poly-L/D-lactide Implant (RegJoint) Versus Tendon Interposition for Trapeziometacarpal Inflammatory Arthritis: a 15-year Follow-up
This is a late (about 15 years) follow-up study of a randomized prospective clinical study originally conducted as a collaboration of the Rheumatism Foundation Hospital, Heinola, Finland and Päijät-Häme Central Hospital, Lahti…
- Trial name
- NCT06804356
- Testing
- Tendon interposition arthroplasty, Poly-L-D-lactic acid implant (RegJoint) interposition arthroplasty
- Where
- Finland
- Volunteers
- 21 people
- Sponsor
- Helsinki University Central Hospital
Hypoxic-Ischemic Encephalopathy, Birth Asphyxia
Umbilical Cord Milking in Neonates Who Are Depressed at Birth-Developmental Follow Up (MIDAB-FU)
An extension of the MIDAB trial, the MIDAB-Follow-up trial will evaluate the neurodevelopmental outcomes at 22-26 months age of term/late preterm infants who were depressed at birth and received umbilical cord milking (UCM) or…
- Trial name
- MIDAB-FU (NCT03681314)
- Testing
- Umbilical Cord Milking
- Where
- 3 sites in India
- Sponsor
- Nemours Children's Clinic
Open Angle Glaucoma, Ocular Hypertension
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
This is a Phase III Study that includes a single arm, open-label, multi-dose PK study cohort and a randomized, evaluator-masked, active drug-control multicenter study.
- Trial name
- NCT06666855
- Testing
- DE-117B Eye Drops, Latanoprost
- Where
- 24 sites in China
- Volunteers
- 345 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Age Related Macular Degeneration
Retinal Pigment Epithelium Safety Study for Patients in B4711001
This is a safety follow-up study. Patients enrolled in B4711001 will be followed for a further 4 years with regular visits to assess safety.
- Trial name
- NCT03102138
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Neoplasms
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
- Trial name
- NCT03391778
- Testing
- ADP adoptive cell therapy
- Where
- 24 sites in United States, Australia and 6 more
- Volunteers
- 250 people
- Sponsor
- USWM CT, LLC
Surgery, Incisional Hernia
Suture Techniques to Reduce the Incidence of Incisional Hernia: LTFU STITCH Trial
Rationale: Incisional hernias (IH) are a frequent complication after abdominal surgery. Prevalence of an IH varies depending on the previous abdominal procedure but could be as high as 70% in high-risk patients after open…
- Conditions
- Surgery, Incisional Hernia, Wound Infection, Fascial Dehiscence
- Trial name
- LTFU-STITCH (NCT06066385)
- Testing
- Small bites technique, Conventional large bites closure
- Where
- 9 sites in Netherlands
- Volunteers
- 560 people
- Sponsor
- Erasmus Medical Center
Transfusion-dependent Beta-Thalassemia
Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy
This is a multi-center, long-term safety and efficacy follow-up study for subjects with transfusion-dependent β-thalassemia (TDT) who have been treated with ex vivo gene therapy drug product in bluebird bio-sponsored parent…
- Trial name
- NCT02633943
- Testing
- Safety and efficacy assessments
- Where
- 15 sites in United States, Australia and 6 more
- Volunteers
- 66 people
- Sponsor
- Genetix Biotherapeutics Inc.
Edentulous Alveolar Ridge
Long-term Follow up of Mucosal Tissue Height Influence on Peri-implant Bone Levels.
Our study looks into how the thickness of the gum tissue affects the health of the bone around dental implants over ten years. We include 59 people and divide them into three groups based on their gum tissue thickness.
- Trial name
- NCT06302322
- Testing
- Thin Tissues, Thick Tissues, Surgically augmented thin tissues
- Where
- Lithuania
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Harvard Medical School (HMS and HSDM)
Age-Related Macular Degeneration
Dark Adaptation in Participants With Age-Related Macular Degeneration
Background: Macular degeneration can cause permanent loss of central vision. This vision is important for seeing details. Age-related macular degeneration (AMD) is the leading cause of vision loss in people over 55 in the United…
- Trial name
- NCT03225131
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Eye Institute (NEI)
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.
Master Protocol: The main goal of this master clinical trial study is to assesses the safety, tolerability, pharmacokinetic (PK), Pharmacodynamic (PD) in participants with relapsed or refractory acute myeloid leukemia (AML) or…
- Trial name
- NCT05457010
- Testing
- SPRX002, ARC-T Cells, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Kite, A Gilead Company
Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
- Conditions
- Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma
- Trial name
- NCT06116110
- Testing
- Long-term Follow-Up
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Miltenyi Biomedicine GmbH
Breast Cancer Invasive
Long-term Follow-up of the TAM-01 Study and Pooled Analysis of Low-dose Tamoxifen Studies in Non-invasive or Microinvasive Breast Neoplasms
Low-dose tamoxifen (5 mg/day for three years, BabyTam) has emerged as a safer and effective alternative to the standard regimen (20 mg/day), reducing breast cancer recurrence with fewer adverse events.
- Trial name
- Babytam long (NCT06982313)
- Testing
- Tamoxifen (Nolvadex)
- Where
- 2 sites in Italy
- Volunteers
- 1,545 people
- Sponsor
- Ente Ospedaliero Ospedali Galliera